The phase of perovskite evolves when the non-stoichiometric mixed halide precursor is baked at different temperatures. Nb-doped TiO2nanorods are superior to plain nanorods as electron transport medium in crystallized perovskite.

All-inorganic cesium lead-halide perovskites exhibit a great development prospect in optoelectronic devices owing to their stability and remarkable optoelectronic properties. Herein, we investigate the solution-processed synthesis of perovskite CsPb2Br5 nanosheets by using aqueous and ethanol as solvents. The results show that the aqueous environment ensures the phase formation of CsPb2Br5 and that the supersaturated solution in ethanol boosts nucleation of the nanosheets. The substrate temperature is the key factor for the evolution of morphology and the variation of the thickness of CsPb2Br5 nanosheets. Lower substrate temperature (<35 °C) is conducive to the formation of evenly distributed nanosheets with less stacking. The spatial and time-resolved fluorescence spectra indicate the heterogeneity of the defect density and the recombination process in different nanosheet regions. The photodetector based on the prepared CsPb2Br5 nanosheet displays an excellent switching current ratio (9 × 102), a short rise and decay time (43 and 83 ms, respectively), and good stability (75% of the initial current after 90 days in air). In addition, the mechanical stability and flexibility of the photodetector on the flexible substrate are investigated for 500 bending cycles.

Previous studies have shown that hepatitis B core antibody (anti-HBc) levels vary during different phases of disease in treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of both interferon-α and nucleoside analogue therapy response. However, there is no information on the association between the quantitative serum anti-HBc (qAnti-HBc) level and liver inflammation in CHB patients. Therefore, we investigated these relationships in a large cohort of treatment-naïve CHB patients. A total of 624 treatment-naïve CHB patients were included in the study. The serum qAnti-HBc level was moderately correlated with ALT and AST levels (P < 0.001) in both hepatitis B e antigen-positive (HBeAg [+]) and HBeAg-negative (HBeAg [−]) CHB patients. CHB patients with no to mild inflammation (G0–1) had significantly lower serum qAnti-HBc levels than patients with moderate to severe inflammation (G2–4) (P < 0.001). Receiver operating characteristic analysis suggested that a serum qAnti-HBc cut-off value of 4.36 log10 IU/mL provided a sensitivity of 71.68%, specificity of 73.81%, positive predictive value of 78.43%, and negative predictive value of 66.24% in HBeAg (+) CHB patients with moderate to severe inflammation (G≥2). A cut-off value of 4.62 log10 IU/mL provided a sensitivity of 54.29%, specificity of 90.00%, positive predictive value of 95.00%, and negative predictive value of 36.00% in HBeAg (−) CHB patients with moderate to severe inflammation (G≥2). Serum qAnti-HBc levels were positively associated with liver inflammation grade. Furthermore, we identified optimal serum qAnti-HBc cut-off values for the prediction of inflammation activity in both HBeAg (+) and HBeAg (−) treatment-naïve CHB patients.